Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Core Viewpoint - Novo Nordisk has been trending as a highly searched stock, with a recent performance of +8.4% over the past month, outperforming the S&P 500 composite's +5% and the Large Cap Pharmaceuticals industry's +6.3% [1] Earnings Estimates Revisions - For the current quarter, Novo Nordisk is expected to report earnings of $0.83 per share, reflecting a +31.8% change year-over-year, with a +0.8% revision in the consensus estimate over the last 30 days [3] - The consensus earnings estimate for the current fiscal year is $3.39, indicating a +25.6% change from the previous year, with a +2.3% revision in the last 30 days [3] - For the next fiscal year, the consensus estimate is $4.28, showing a +26.3% change year-over-year, with a +4.7% revision over the past month [3] Revenue Growth Projections - The consensus sales estimate for the current quarter is $9.95 billion, indicating a +25.4% year-over-year change [5] - For the current fiscal year, the sales estimate is $42.42 billion, reflecting a +25.9% change, while the next fiscal year's estimate is $52.35 billion, indicating a +23.4% change [5] Last Reported Results - Novo Nordisk reported revenues of $9.52 billion in the last quarter, representing a +23.7% year-over-year change, with an EPS of $0.83 compared to $0.64 a year ago [6] - The reported revenues exceeded the Zacks Consensus Estimate of $9.23 billion by +3.15%, and the EPS surprise was +7.79% [6] Performance History - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [7] Valuation Insights - Novo Nordisk's current valuation metrics suggest it is trading at a premium compared to its peers, as indicated by a Zacks Value Style Score of D [9] Conclusion - The Zacks Rank of 3 for Novo Nordisk suggests it may perform in line with the broader market in the near term, despite the market buzz surrounding the stock [10]